Navigation Links
CTI Seeks Strategic Alternative for Italian Facility
Date:2/6/2009

Spin-off would reduce CTI burn rate by $14 million

SEATTLE, Feb. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has engaged the services of a strategic advisory consulting firm, Adjuvant Global Advisors, LLC, (Adjuvant) to assist in developing strategic options for a partnership, asset divestment or joint venture for Cell Therapeutics Europe Sede Secondaria (CTE), the preclinical drug development arm of CTI, in Bresso, Milan. The move is designed to narrow the focus of CTI's business plan, reducing its burn rate by $14 million as it also maintains the mission and workforce of the Bresso facility.

"As CTI transitions from a research-based operation to a commercial drug company, it has been transferring resources to its U.S. sales and marketing operations," said James A. Bianco, M.D., CEO of CTI. "As we have previously announced, we are refocusing our resources on late-stage and marketed products, and as such, CTI needs to reduce its preclinical operations."

Adjuvant's role will be to seek out a potential buyer or partner for the Bresso facility, with the aim of identifying organizations that want to expand with an intact and integrated preclinical team.

"Bresso is an acquisition opportunity for clinical research organizations or pharmaceutical companies to acquire a productive GLP compliant research and development asset that has a proven track record in advancing molecules from discovery to clinic," said Christina Waters, Ph.D., M.B.A., President, CTE and Systems Medicine LLC.

The Bresso personnel have worked together in oncology for many years and offer fully-integrated services ranging from Target discovery, Lead discovery and optimization, Preclinical development (non-GLP/GLP), along with preclinical activities supporting Clinical development (Phase I - Phase III, and Regulatory (EU/USA). The organization is
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Universal Bioenergy, Inc. Seeks Algae Feedstock Companies for Acquisition, Alliance, and Joint Venture Opportunities for Biodiesel Production
2. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
3. NIU Seeks OK for New Proton Cancer Treatment and Research Center
4. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
5. GBC Seeks Nominations for Regions Third Annual Bioscience Awards
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. Advanced Instruments Makes Strategic Investment in Cantimer, Inc.
8. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
9. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
10. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
11. P2R Associates Presented with Eight MarCom Awards for Client Strategic Communication Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the third quarter ended September 30,2007. ... for the three months ended September 30, 2007 ...
... MS, EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2007. "During the quarter, we continued to ... MBP8298, for the treatment of multiple,sclerosis," said Kevin ...
... Micromet, Inc.,(Nasdaq: MITI ) ("Micromet" or ... for the treatment of cancer,inflammation and autoimmune diseases, ... Company appointed Joseph P. Slattery as a member ... committee. The appointment will be,effective as of November ...
Cached Biology Technology:Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 2Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 3Micromet, Inc. Elects Joseph P. Slattery to Board of Directors 4
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of serum long-chain omega-3 fatty acids may help reduce the ... Eastern Finland study published recently in Diabetes Care . ... oils. Type 2 diabetes is becoming increasingly widespread throughout ... factor, which means that diet and other lifestyle factors play ...
... launches today, investigating the social and political drivers and ... carbon dioxide emitter by volume, rather than focusing on ... worldwide we need to transform the way we power ... And nowhere is the approach to innovation across these ...
... been awarded to Cynthia Graber for her feature ,Electric ... regeneration?, published at MATTER. In ... journalist based in Massachusetts, investigates the work of Professor ... and Developmental Biology, to improve our understanding of the ...
Cached Biology News:Fish derived serum omega-3 fatty acids help reduce the risk of type 2 diabetes 2Story of human regeneration wins international physics journalism prize 2
... harvesting of cells • Blade design minimizes ... the growth surface • Designed for use ... wrapped • Sterilized by gamma radiation and ... a new product number, created to easily ...
... The MagneGST™ Protein Purification System ... method for the purification of glutathione-S-transferase ... particles (MagneGST™ Particles) are used to ... crude or cleared lysate using either ...
... versatile system that simultaneously harvests and washes ... into a solid filter supports for analysis ... counter. The FilterMate is ideal for the ... cell proliferation, receptor binding, nucleic acid degradation, ...
... A ready-to-use kit for a single fragment based screening project: ... each) , 96 shape-diverse mixtures of ... and dictionary files for structure refinement , ... of 4 are at ca. 50 mM. Supplied in 5 ...
Biology Products: